Prevalence of overweight and obesity in adolescents with severe mental illness: a cross-sectional chart review.
OBJECTIVE
Pediatric obesity (body mass index [BMI] > or = 95th percentile for sex and age) and overweight (BMI > or = 85th percentile < 95% percentile) are priority public health targets for the prevention of diabetes and cardiovascular disease. We examined the prevalence and risk of overweight and obesity in adolescents with serious mental disorders.


METHODS
Height, weight, demographic, diagnostic, and treatment data were reviewed for 114 adolescents attending a partial hospitalization program over 18 consecutive months between January 2003 and July 2004. Sample data were compared to normative National Health and Nutrition Examination Survey data and regional county data for BMI. Unadjusted odds ratios and their 95% CIs were calculated for each categorical risk factor using the chi-squared test. A logistic regression model was conducted to detect the effects of these risk factors on the occurrence of overweight and obesity.


RESULTS
The combined prevalence of overweight and obesity was 55.4% (n = 63); the prevalence for obesity alone was 30% (n = 34), approximately double the rate in national and county norms. Lack of private insurance, smoking, and antidepressant and antipsychotic treatment were associated with overweight and obese status.


CONCLUSIONS
Adolescents with severe mental illness are at increased risk for overweight and obesity. Identification of elevated BMI, associated risk factors, and efforts to prevent weight gain should begin at initiation of mental health treatment.
Gracious
Barbara L
BL
Department of Psychiatry, University of Rochester Medical Center, 300 Crittenden Blvd., Rochester, NY 14642, USA. Barbara_Gracious@urmc.rochester.edu
Cook
Stephen R
SR
Meyer
Ashley E
AE
Chirieac
Madalina C
MC
Malhi
Namrita
N
Fischetti
Anthony T
AT
Finucane
Teresa L
TL
Ma
Yan
Y
D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D003430:Cross-Sectional Studies; D003631:Day Care, Medical / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D019458:Insurance Coverage / Q000706:statistics & numerical data; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000453:epidemiology*; D009426:Netherlands; D009765:Obesity / Q000139:chemically induced* / Q000453:epidemiology*; D050177:Overweight / Q000139:chemically induced* / Q000453:epidemiology*; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology
D000927:Anticonvulsants; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs